

## Press Release



### NutrigeneAI Receives Innovative Organization (SMEs) Special Award at the HKMA/HKT Global Innovation Award Ceremony

2026, Hong Kong –

NutrigeneAI Biotech Limited is pleased to announce that it has been awarded the Innovative Organization (SMEs) Special Award at the HKMA/HKT Global Innovation Award Ceremony, held as part of HKMA Global Innovation Day.

This recognition marks an important milestone for NutrigeneAI, acknowledging the company's continued commitment to biotechnology innovation, research commercialization and the development of next-generation solutions for vascular health. The award also reflects the growing recognition of NutrigeneAI within Hong Kong's dynamic innovation and technology ecosystem.



HKMA Global Innovation Day is an important platform that brings together innovators from large corporations, small and medium-sized enterprises, startups, research institutions, social organizations and government-related bodies. The event focuses on emerging technology trends, industrial transformation, business model innovation and the creation of social value through innovation.

The program featured an innovation summit, project showcases, final adjudication sessions, exhibition activities, an award presentation ceremony and networking opportunities with innovation leaders. By joining the event, NutrigeneAI was able to present its latest progress, connect with stakeholders across Hong Kong and the Greater Bay Area, and further strengthen its role as a locally rooted biotechnology company advancing scientific innovation toward real-world application.



Founded upon research achievements from The Chinese University of Hong Kong, NutrigeneAI is an innovative biotechnology company dedicated to the development and translation of functionally enhanced induced pluripotent stem cell-derived endothelial cell therapies, or iPSC-EC therapies, and its Type II cytokine pre-activation technology platform.

The company focuses on ischemic vascular diseases and tissue repair, with particular attention to areas of significant unmet clinical need, including peripheral artery disease, critical limb ischemia and diabetic foot ulcers. NutrigeneAI is also exploring broader application scenarios related to vascular repair, vascular regeneration and tissue microenvironment improvement.

Unlike conventional cell therapy approaches that mainly rely on paracrine signaling, NutrigeneAI's technology strategy is designed to enhance endothelial cell function, support vascular structural repair and improve the local tissue microenvironment. Through this approach, the company aims to advance cell therapy from signal regulation toward structural restoration and functional reconstruction.

NutrigeneAI remains committed to translating frontier life science research into clinically relevant and accessible healthcare solutions. The company is currently advancing the

establishment of a GMP-grade cell manufacturing system, preclinical research, quality control development and preparation for future clinical translation. At the same time, NutrigeneAI continues to strengthen collaboration with hospitals, research institutions and industry partners to accelerate the development and implementation of its technology platform.

Supported by Hong Kong's expanding innovation and technology ecosystem, as well as the broader development momentum of the Greater Bay Area, NutrigeneAI will continue to leverage its strengths in academic translation, clinical collaboration, industrial partnerships and market-oriented development to contribute new momentum to the life and health technology sector.



The Innovative Organization (SMEs) Special Award is both a recognition of NutrigeneAI's progress to date and a motivation for the company's continued development. NutrigeneAI extends its sincere appreciation to HKMA, HKT, the judging panel, its research team, clinical collaborators, industry partners and all supporters who have contributed to the company's journey.

Looking ahead, NutrigeneAI will continue to uphold its mission of restoring the body's vital circulatory pathways and reshaping vascular health. With a focus on vascular health and

cell therapy innovation, the company will continue to advance research commercialization with higher standards, stronger translational capabilities and a long-term commitment to addressing unmet clinical needs.

NutrigeneAI believes that meaningful innovation comes not only from technological breakthroughs, but also from sustained attention to human health challenges and long-term investment in scientific progress. Rooted in Hong Kong, connected to the Greater Bay Area and oriented toward the global healthcare landscape, NutrigeneAI will continue to drive the next generation of vascular repair technologies toward a broader future.

—Ends—

Media Contact:  
Communications Office  
NutrigeneAI Biotech Limited  
coby.ke@nutrigeneai.com